Table 5 Registered BTKi Trials of CNS Lymphoma on ClinicaTrial.gov
From: Current and emerging therapies for primary central nervous system lymphoma
Trial | N | Recruited condition | Study | Intervention regimen | Location |
|---|---|---|---|---|---|
NCT03581942 | 45 | PCNSL, r/r | Ib/II | dose escalation ibrutinib+copanlisib | USA |
NCT03770416 | 40 | PCNSL/SCNSL, r/r | II | ibrutinib+nivolumab | USA |
NCT02315326 | 63 | PCNSL/SCNSL, r/r | I/II | dose escalation ibrutinib+HD-MTX+rituximab | USA |
NCT02623010 | 30 | PCNSL after CR/PR | II | ibrutinib in maintenance | Israel |
NCT03703167 | 40 | PCNSL/SCNSL, r/r | Ib | dose escalation ibrutinib+lenalidomide+rituximab | USA |
NCT04421560 | 37 | PCNSL, relapse | Ib/II | dose escalation ibrutinib+ pembrolizumab +rituximab | USA |
NCT04129710 | 120 | PCNSL, r/r | II, RCT | ibrutinib+MRE vs lenalidomide+MRE | China |
NCT04066920 | 30 | PCNSL, r/r, transplant ineligible | II | IBER in induction +ibrutinib in maintenance | Korea |
NCT02203526 | 52 | PCNSL | I | TEDDi-R+isavuconazole | USA |
NCT03964090 | 32 | SCNSL | II | TEDDi-R+isavuconazole | USA |
NCT04446962 | 128 | PCNSL, ND | Ib/II, randomized | dose escalation R-MVP+ibrutinib vs R-MVP+lenalidomide | France |
NCT04462328 | 21 | PCNSL/SCNSL | I | dose escalation acalabritinb+durvalumab | USA |
NCT04438044 | 39 | PCNSL/SCNSL, r/r | II | orelabrutinib | China |